Profound Medical Corp (PROF)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $268.84M
Last updated: Nov 17, 2026 at 4:10 PM ET
Profound Medical Corp (PROF) Statistics
Profound Medical (PROF) has a market cap of $268.84M and an enterprise value of $240.01M. It kept -137.51% of revenue as net income over the last 12 months. Its share count is up 21.43% from a year earlier.
Total Valuation
Enterprise value is 10.72% below the market cap, as cash exceeds debt.
| Market Cap | $268.84M |
|---|---|
| Enterprise Value | $240.01M |
| Latest price (Nov 17, 2026) | $7.08 |
Key Dates
| Last Earnings Date | Nov 5, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 11.0x and 6.1x. Its year-end P/S ranged from 8.6x to 46.4x from 2017 to 2025.
| P/S Ratio | 11.0x |
|---|---|
| Forward P/S | 7.5x |
| P/B Ratio | 6.1x |
| P/TBV Ratio | 6.1x |
Price Statistics
The stock is up 3.36% over 52 weeks and trades 12.03% above its 50-day average.
| Beta (1Y) | 1.41 |
|---|---|
| 52-Week Change | +3.36% |
| 1-Month Change | +20.82% |
| 6-Month Change | +5.20% |
| 5-Year Change | -51.37% |
| 10-Year Change | -17.36% |
| Total Return (1Y) | +3.36% |
| Total Return (3Y CAGR) | -12.75% |
| Total Return (5Y CAGR) | -9.93% |
| Return vs SPY (1Y) | +2.08% |
| Max Drawdown (1Y) | -41.50% |
| Max Drawdown (3Y) | -65.38% |
| Sharpe Ratio (1Y) | 0.18 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $6.32 |
| 200-Day Average | $6.64 |
| 52-Week Range | $4.80 to $8.95 |
| RSI (14 Days) | 55.1 |
| Average Volume (20 Days) | 196.07K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.54x current liabilities, and total debt is 0.11x shareholder equity.
| Current Ratio | 4.54x |
|---|---|
| Quick Ratio | 3.70x |
| Debt / Equity | 0.11x |
Returns and Efficiency
Return on invested capital is -71.15% over the last 12 months, against a 5-year average of -54.99%.
| Return on Equity (ROE) | -76.42% |
|---|---|
| Return on Assets (ROA) | -55.87% |
| Return on Invested Capital (ROIC) | -71.15% |
| ROA (5Y Average) | -47.77% |
| ROIC (5Y Average) | -54.99% |
| Asset Turnover | 0.47x |
| Inventory Turnover | 0.60x |
| Receivables Turnover | 2.29x |
| Cash Conversion Cycle | 712 days |
Scores
PROF has an Altman Z-Score of 1.81, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.81 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $23.63M over the last 12 months is up 65.26% from the 12 months before.
| Revenue | $23.63M |
|---|---|
| Revenue Growth (YoY) | +65.26% |
| Gross Profit | $17.45M |
| Operating Income | -$34.28M |
| Pretax Income | -$32.39M |
| Net Income | -$32.49M |
| Reported EPS (TTM) | -$0.41 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 73.10% of the $58.15M in total assets.
| Cash and Equivalents | $33.34M |
|---|---|
| Total Debt | $4.51M |
| Net Cash | $28.83M |
| Net Cash Per Share | $0.79 |
| Working Capital | $42.77M |
| Shareholder Equity | $42.51M |
| Book Value Per Share | $1.16 |
| Tangible Book Value | $42.40M |
| Tangible Book Per Share | $1.16 |
| Total Assets | $58.15M |
| Total Liabilities | $15.64M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$31.49M |
|---|---|
| FCF Per Share | -$0.87 |
| Depreciation and Amortization | $477.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -145.08%.
| Gross Margin | 73.86% |
|---|---|
| Operating Margin | -145.08% |
| Pretax Margin | -137.08% |
| Net Margin | -137.51% |
| Gross Margin (5Y Average) | 56.95% |
Growth
Revenue grew 34.06% a year over 3 years.
| Revenue Growth (3Y CAGR) | +34.06% |
|---|---|
| Revenue Growth (5Y CAGR) | +17.12% |
| Book Value Per Share Growth (2Y CAGR) | +21.65% |
| Tangible Book Per Share Growth (2Y CAGR) | +22.49% |
Dividends and Yields
PROF does not pay a dividend.
| Buyback Yield | -16.40% |
|---|---|
| Shareholder Yield | -16.40% |
Stock Splits
The last split was a 1-for-10 reverse split on Oct 16, 2019.
| Last Split Date | Oct 16, 2019 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Analyst Forecast
Consensus estimates put revenue growth at 94.75% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +94.75% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PROF
What is PROF's market cap?
Profound Medical has a market cap of $268.84M. Its enterprise value, which adds debt and subtracts cash, is $240.01M.
How many shares of PROF are outstanding?
Profound Medical has 36.56M shares outstanding. The count is up 21.43% from a year earlier.
Does PROF pay a dividend?
No. Profound Medical does not pay a dividend.
How much debt does PROF have?
Profound Medical has $4.51M of total debt and $33.34M of cash and equivalents, a net cash position of $28.83M.
PROF pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation